Zebrafish Model for Drug Discovery and Screening
Zebrafish Model for Biomedical Research, Page: 229-258
2022
- 6Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures6
- Readers6
Book Chapter Description
The zebrafish as a preclinical drug development model is discussed considering different aspects. 3-Rs Replacement, Reduction and Refinement related to zebrafish for drug discovery are discussed. The strength of zebrafish as a model for preclinical drug development is highlighted. The different aspects of drug development considering the genetics of zebrafish are well covered. Phenotype-based drug development, structure-activity relationship, target-based drug development and toxicities related to zebrafish are elaborated with suitable examples. Organs like heart, liver, intestines, kidney, CNS, haemopoietic system, endocrine system and their drug development-related aspects like pharmacokinetics and drug toxicities in zebrafish are elaborated. Separate topic is dedicated to cancer drug development using zebrafish. Drug resistance related to P-glycoprotein and other related mechanisms is also covered. Practical limitations in use of zebrafish as preclinical drug development models are addressed.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85162654729&origin=inward; http://dx.doi.org/10.1007/978-981-16-5217-2_11; https://link.springer.com/10.1007/978-981-16-5217-2_11; https://dx.doi.org/10.1007/978-981-16-5217-2_11; https://link.springer.com/chapter/10.1007/978-981-16-5217-2_11
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know